Published in Annu Rev Pharmacol Toxicol on January 01, 2002
Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature (2011) 13.92
Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol (2009) 6.66
G protein-coupled receptor rhodopsin. Annu Rev Biochem (2006) 4.95
Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature (2008) 4.09
Roles of G-protein-coupled receptor dimerization. EMBO Rep (2004) 3.33
Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev (2010) 3.27
Regulation of CXCR4 signaling. Biochim Biophys Acta (2006) 3.16
The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther (2006) 3.15
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A (2004) 3.00
Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J Biol Chem (2007) 2.59
G protein coupled receptor structure and activation. Biochim Biophys Acta (2006) 2.48
Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci U S A (2005) 2.33
Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev (2010) 2.30
The G protein-coupled receptor rhodopsin in the native membrane. FEBS Lett (2004) 2.19
G protein-coupled receptor rhodopsin: a prospectus. Annu Rev Physiol (2002) 2.08
Analysis of receptor oligomerization by FRAP microscopy. Nat Methods (2009) 2.06
Crystal structure of oligomeric β1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat Struct Mol Biol (2013) 2.06
FRET imaging reveals that functional neurokinin-1 receptors are monomeric and reside in membrane microdomains of live cells. Proc Natl Acad Sci U S A (2006) 2.04
Oligomerization of G protein-coupled receptors: past, present, and future. Biochemistry (2004) 2.03
mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol (2006) 1.93
Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. Proc Natl Acad Sci U S A (2005) 1.91
Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest (2006) 1.82
Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc Natl Acad Sci U S A (2012) 1.82
Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol (2012) 1.73
Each rhodopsin molecule binds its own arrestin. Proc Natl Acad Sci U S A (2007) 1.73
Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J (2005) 1.72
Rhodopsin signaling and organization in heterozygote rhodopsin knockout mice. J Biol Chem (2004) 1.64
Functional characterization of rhodopsin monomers and dimers in detergents. J Biol Chem (2004) 1.57
Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes. EMBO J (2004) 1.55
The origins of diversity and specificity in g protein-coupled receptor signaling. J Pharmacol Exp Ther (2005) 1.53
Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol (2003) 1.49
The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol Rev (2011) 1.39
Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc Natl Acad Sci U S A (2004) 1.38
Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration. EMBO J (2009) 1.32
The receptor concept: pharmacology's big idea. Br J Pharmacol (2006) 1.25
The supramolecular structure of the GPCR rhodopsin in solution and native disc membranes. Mol Membr Biol (2005) 1.23
Heterodimerization, trafficking and membrane topology of the two proteins, Ost alpha and Ost beta, that constitute the organic solute and steroid transporter. Biochem J (2007) 1.22
Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem (2002) 1.17
Efficiency of resonance energy transfer in homo-oligomeric complexes of proteins. J Biol Phys (2007) 1.17
Protein interaction quantified in vivo by spectrally resolved fluorescence resonance energy transfer. Biochem J (2005) 1.16
Modulation of chemokine receptor activity through dimerization and crosstalk. Cell Mol Life Sci (2009) 1.15
Formation of mu-/kappa-opioid receptor heterodimer is sex-dependent and mediates female-specific opioid analgesia. Proc Natl Acad Sci U S A (2010) 1.11
Multiple serotonergic mechanisms contributing to sensitization in aplysia: evidence of diverse serotonin receptor subtypes. Learn Mem (2003) 1.09
Organization of higher-order oligomers of the serotonin₁(A) receptor explored utilizing homo-FRET in live cells. Biophys J (2011) 1.08
Cell-surface targeting of alpha2-adrenergic receptors -- inhibition by a transport deficient mutant through dimerization. Cell Signal (2005) 1.07
Structural basis of M3 muscarinic receptor dimer/oligomer formation. J Biol Chem (2011) 1.06
Computational modeling reveals how interplay between components of a GTPase-cycle module regulates signal transduction. Proc Natl Acad Sci U S A (2004) 1.06
Rhodopsin-transducin heteropentamer: three-dimensional structure and biochemical characterization. J Struct Biol (2011) 1.05
N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers. Proc Natl Acad Sci U S A (2011) 1.05
Secretin receptor oligomers form intracellularly during maturation through receptor core domains. Biochemistry (2006) 1.05
Coordinate regulation of estrogen-mediated fibronectin matrix assembly and epidermal growth factor receptor transactivation by the G protein-coupled receptor, GPR30. Mol Endocrinol (2009) 1.05
Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol (2011) 1.05
Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits β-arrestin-mediated endosomal signaling. J Biol Chem (2013) 1.03
Subcellular distribution of GABA(B) receptor homo- and hetero-dimers. Biochem J (2005) 1.03
Oligomeric size of the m2 muscarinic receptor in live cells as determined by quantitative fluorescence resonance energy transfer. J Biol Chem (2010) 1.03
Efficient determination of protein-protein standard binding free energies from first principles. J Chem Theory Comput (2013) 1.02
Crystal packing analysis of Rhodopsin crystals. J Struct Biol (2007) 1.02
Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS J (2006) 1.02
Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization. Biophys J (2008) 1.01
Structure and function of G protein-coupled receptors using NMR spectroscopy. Prog Nucl Magn Reson Spectrosc (2010) 1.00
Promiscuous dimerization of the growth hormone secretagogue receptor (GHS-R1a) attenuates ghrelin-mediated signaling. J Biol Chem (2012) 0.97
Orphan GPCR research. Br J Pharmacol (2007) 0.97
Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J Neural Transm (Vienna) (2006) 0.95
Structural aspects of M₃ muscarinic acetylcholine receptor dimer formation and activation. FASEB J (2011) 0.95
A bivalent ligand (KMN-21) antagonist for mu/kappa heterodimeric opioid receptors. Bioorg Med Chem Lett (2009) 0.94
The α1-adrenergic receptors: diversity of signaling networks and regulation. J Recept Signal Transduct Res (2010) 0.94
The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers. J Biol Chem (2013) 0.93
Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process. J Biol Chem (2009) 0.92
GPR80/99, proposed to be the P2Y(15) receptor activated by adenosine and AMP, is not a P2Y receptor. Purinergic Signal (2004) 0.91
Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. Adv Pharmacol (2011) 0.91
Segregation of family A G protein-coupled receptor protomers in the plasma membrane. Mol Pharmacol (2013) 0.91
Comparison between whole distribution- and average-based approaches to the determination of fluorescence resonance energy transfer efficiency in ensembles of proteins in living cells. Biophys J (2010) 0.90
Direct observation of individual KCNQ1 potassium channels reveals their distinctive diffusive behavior. J Biol Chem (2009) 0.89
'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Br J Pharmacol (2011) 0.88
Therapeutic role and ligands of medium- to long-chain Fatty Acid receptors. Front Endocrinol (Lausanne) (2014) 0.87
The physical association of the P2Y12 receptor with PAR4 regulates arrestin-mediated Akt activation. Mol Pharmacol (2014) 0.86
Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors. Biochim Biophys Acta (2013) 0.86
Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend (2011) 0.85
The alpha1D-adrenergic receptor is expressed intracellularly and coupled to increases in intracellular calcium and reactive oxygen species in human aortic smooth muscle cells. J Mol Signal (2008) 0.85
Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation. Am J Physiol Gastrointest Liver Physiol (2008) 0.84
Kappa and delta opioid receptor signaling is augmented in the failing heart. J Mol Cell Cardiol (2009) 0.84
A hypothesis for GPCR activation. J Mol Model (2005) 0.83
Complement component 5a receptor oligomerization and homologous receptor down-regulation. J Biol Chem (2008) 0.83
Biophysical Detection of Diversity and Bias in GPCR Function. Front Endocrinol (Lausanne) (2014) 0.82
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2. Assay Drug Dev Technol (2010) 0.82
A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer. Methods Mol Biol (2013) 0.82
Modeling dimerizations of transmembrane proteins using Brownian dynamics simulations. J Comput Aided Mol Des (2008) 0.81
Protein-protein interactions at the adrenergic receptors. Curr Drug Targets (2012) 0.81
A context-dependent combination of Wnt receptors controls axis elongation and leg development in a short germ insect. Development (2011) 0.81
Computational study of the heterodimerization between mu and delta receptors. J Comput Aided Mol Des (2009) 0.81
Transcriptome Bioinformatical Analysis of Vertebrate Stages of Schistosoma japonicum Reveals Alternative Splicing Events. PLoS One (2015) 0.80
Novel structural and functional insights into M3 muscarinic receptor dimer/oligomer formation. J Biol Chem (2013) 0.80
Serotonin 5-HT(2C) receptor homodimerization is not regulated by agonist or inverse agonist treatment. Eur J Pharmacol (2007) 0.80
Membrane-Mediated Oligomerization of G Protein Coupled Receptors and Its Implications for GPCR Function. Front Physiol (2016) 0.79
Role of antibodies in developing drugs that target G-protein-coupled receptor dimers. Mt Sinai J Med (2010) 0.79
Regulation, Signaling, and Physiological Functions of G-Proteins. J Mol Biol (2016) 0.79
Homodimerization as a molecular switch between low and high efficiency PrP C cell surface delivery and neuroprotective activity. Prion (2013) 0.79
The effect of membrane domains on the G protein-phospholipase Cbeta signaling pathway. Crit Rev Biochem Mol Biol (2010) 0.79
Demonstration of a direct interaction between β2-adrenergic receptor and insulin receptor by BRET and bioinformatics. PLoS One (2014) 0.79
Mont Sainte-Odile: a sanctuary for GPCRs. Confidence on signal transduction of G-protein-couple receptors. EMBO Rep (2003) 0.79
Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A (2003) 3.75
Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem (2002) 3.40
Roles of G-protein-coupled receptor dimerization. EMBO Rep (2004) 3.33
Real-time monitoring of receptor and G-protein interactions in living cells. Nat Methods (2005) 2.72
Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol (2006) 2.69
Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci (2005) 2.63
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol (2006) 2.62
The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci (2007) 2.46
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Real-time monitoring of ubiquitination in living cells by BRET. Nat Methods (2004) 2.23
Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J (2005) 2.16
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol (2005) 2.14
Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO J (2002) 2.13
Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem (2005) 2.10
Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem (2010) 2.06
Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting. J Biol Chem (2004) 2.03
Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab (2004) 1.96
Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization. Nat Cell Biol (2003) 1.96
Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem (2003) 1.96
Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci (2007) 1.93
Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J (2005) 1.90
Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A (2008) 1.85
Restructuring G-protein- coupled receptor activation. Cell (2012) 1.83
Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol (2002) 1.76
Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem (2002) 1.68
Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep (2005) 1.65
High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J Biomol Screen (2005) 1.61
Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem (2002) 1.59
Insights into signaling from the beta2-adrenergic receptor structure. Nat Chem Biol (2008) 1.56
Role of palmitoylation/depalmitoylation reactions in G-protein-coupled receptor function. Pharmacol Ther (2003) 1.55
Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes. EMBO J (2004) 1.55
BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods (2007) 1.48
Heterotrimeric G proteins form stable complexes with adenylyl cyclase and Kir3.1 channels in living cells. J Cell Sci (2006) 1.46
A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal (2011) 1.45
Pharmacological chaperone action on G-protein-coupled receptors. Curr Opin Pharmacol (2004) 1.45
Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem (2002) 1.44
Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem (2003) 1.44
Homo- and hetero-oligomerization of beta-arrestins in living cells. J Biol Chem (2005) 1.39
Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem (2004) 1.39
Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc Natl Acad Sci U S A (2004) 1.38
Smoothened signal transduction is promoted by G protein-coupled receptor kinase 2. Mol Cell Biol (2006) 1.38
Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem (2008) 1.34
Experimental challenge to a 'rigorous' BRET analysis of GPCR oligomerization. Nat Methods (2007) 1.32
Phosphorylation-independent desensitization of GABA(B) receptor by GRK4. EMBO J (2003) 1.30
Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Mol Pharmacol (2009) 1.30
Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol Pharmacol (2008) 1.29
Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord (2004) 1.27
Monitoring protein-protein interactions in living cells by bioluminescence resonance energy transfer (BRET). Curr Protoc Neurosci (2006) 1.26
G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. J Biol Chem (2002) 1.23
Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1. J Biol Chem (2007) 1.19
Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). J Biol Chem (2011) 1.19
Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol (2013) 1.19
The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS). J Recept Signal Transduct Res (2002) 1.17
Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. J Biol Chem (2008) 1.17
Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ Res (2005) 1.17
Resonance energy transfer approaches in molecular pharmacology and beyond. Trends Pharmacol Sci (2007) 1.16
Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between beta-arrestins and AP-2. J Biol Chem (2007) 1.15
An evolutionarily conserved autoinhibitory molecular switch in ELMO proteins regulates Rac signaling. Curr Biol (2010) 1.15
Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine. Neuropsychopharmacology (2008) 1.14
Methylphenidate and cocaine self-administration produce distinct dopamine terminal alterations. Addict Biol (2012) 1.13
Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem (2004) 1.12
Distinct subcellular localization for constitutive and agonist-modulated palmitoylation of the human delta opioid receptor. J Biol Chem (2006) 1.11
Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1/2 activation. J Biol Chem (2003) 1.10
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol (2013) 1.10
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
Subcellular imaging of dynamic protein interactions by bioluminescence resonance energy transfer. Biophys J (2007) 1.08
Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci Signal (2012) 1.07
Receptor-regulated interaction of activator of G-protein signaling-4 and Galphai. J Biol Chem (2010) 1.07
The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell Signal (2006) 1.06
Regulation of the AGS3·G{alpha}i signaling complex by a seven-transmembrane span receptor. J Biol Chem (2010) 1.06
Multimerization of Staufen1 in live cells. RNA (2010) 1.05
Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner. Proc Natl Acad Sci U S A (2011) 1.05
Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol (2011) 1.05
A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer. J Virol Methods (2005) 1.04
Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun (2013) 1.04
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol (2004) 1.04
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics (2007) 1.04
Functional rescue of beta-adrenoceptor dimerization and trafficking by pharmacological chaperones. Traffic (2009) 1.03
Subcellular distribution of GABA(B) receptor homo- and hetero-dimers. Biochem J (2005) 1.03
Impedance responses reveal β₂-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. PLoS One (2012) 1.02
Noradrenergic control of cortico-striato-thalamic and mesolimbic cross-structural synchrony. J Neurosci (2010) 1.02
Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Ther (2009) 1.01
Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A (2013) 1.00
Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol (2010) 1.00
A cyclic peptide mimicking the third intracellular loop of the V2 vasopressin receptor inhibits signaling through its interaction with receptor dimer and G protein. J Biol Chem (2004) 1.00
Dynamic anal endosonography and MRI defecography in diagnosis of pelvic floor disorders: comparison with conventional defecography. Dis Colon Rectum (2011) 0.99
Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J Pharmacol Exp Ther (2010) 0.99
Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes. J Biol Chem (2011) 0.98
Optimizing the Temporal Resolution of Fast-Scan Cyclic Voltammetry. ACS Chem Neurosci (2012) 0.98
D1 dopamine receptor coupling to PLCβ regulates forward locomotion in mice. J Neurosci (2013) 0.98
Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. Expert Opin Drug Discov (2011) 0.98
PKA regulatory subunits mediate synergy among conserved G-protein-coupled receptor cascades. Nat Commun (2011) 0.97
Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter. Cell Signal (2008) 0.95
Characterization of oligomeric human ATP binding cassette transporter A1. Potential implications for determining the structure of nascent high density lipoprotein particles. J Biol Chem (2004) 0.95
Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus. Nephron Physiol (2009) 0.95